SAVANT study

Efficacy of Sacubitril/Valsartan and Amlodipine in Cancer Patients with Drug-induced Hypertension caused by Angiogenesis Inhibitor

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1041240078

Enrollment

Registered

2024-08-29

Start date

2024-12-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension caused by Angiogenesis Inhibitor

Interventions

Patient with hypertension due to angiogenesis inhibitor is treated with combination therapy of sacubitril/valsartan200mg and amlodipine5mg. Changes of blood pressure are monitored for 3 weeks (+- 1 we

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Pathologically diagnosed with cancer (2) Diagnosed with drug-induced hypertension caused by angiogenesis inhibitors (3) One calcium antagonist or ARB/ACE inhibitor is used (4) Angiogenesis inhibitor is continued. (5) Creatinine is less than 1.5 mg/dL (6) 18 years or older (7) Written informed consent was obtained

Exclusion criteria

Exclusion criteria: (1)Severe hypertention (CTCAEv5, Grade4) (2)Essential hypertension (Blood pressure 140/90mmHg or more before starting treatment with angiogenesis inhibitors) (3)History of secondary hypertension

Design outcomes

Primary

Measure	Time frame
Rate of blood pressure control	—

Secondary

Measure	Time frame
Adverse events Change of blood-pressure value	—

Contacts

Public ContactTakuya Oyakawa

Shizuoka Cancer Center

t.oyakawa@scchr.jp+81-55-989-5222

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026